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Abstract
Mesenchymal stem cells (MSCs) are multipotent stem cells that can be 
isolated from both foetal and adult tissues. Several groups demonstrated that 
transplantation of MSCs promoted the regeneration of skeletal muscle and 
ameliorated muscular dystrophy in animal models. Mesenchymal stem cells 
in skeletal muscle, also known as fibro-adipogenic progenitors (FAPs), are 
essential for the maintenance of skeletal muscle. Importantly, they contribute to 
fibrosis and fat accumulation in dystrophic muscle. Therefore, MSCs in muscle 
are a pharmacological target for the treatment of muscular dystrophies. In this 
chapter, we briefly update the knowledge on mesenchymal stem/progenitor cells 
and discuss their therapeutic potential as a regenerative medicine treatment of 
Duchenne muscular dystrophy.
Keywords: mesenchymal stem cells, induced pluripotent stem cells, induced 
MSCs, Duchenne muscular dystrophy, immune response, paracrine factors, cell 
transplantation, muscle regeneration, dystrophin, satellite cells, inflammation, 
skeletal muscle, fibrosis, adipocyte
1. Introduction
Duchenne muscular dystrophy (DMD) is an X-linked progressive muscle wasting 
disorder caused by mutations in the DMD gene [1, 2], affecting 1 in 3500–5000 male 
births. Serum creatine kinase (CK) levels are elevated at birth, and motor milestones 
are delayed. Reduced motor skills between age 3 and 5 years provoke diagnostic 
evaluation. Quality of life for boys with DMD is further affected early in life, with 
the inability to keep up with peers of early school age and loss of ambulation by 
12 years of age; premature death occurs at 20–30 years of age due to respiratory and 
cardiac complications (https://www.duchenne.com/about-duchenne; https://ghr.
nlm.nih.gov/condition/duchenne-and-becker-muscular-dystrophy).
Mutations of the DMD gene cause complete (Duchenne) or partial (Becker) loss 
of dystrophin protein at the sarcolemma [3]. In normal muscle cells, dystrophin 
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forms a complex with glycoproteins at the sarcolemma, forming a critical link 
between the extracellular matrix (ECM) and the cytoskeleton [4]. Without the 
complex, the sarcolemma becomes fragile and is easily disrupted by mechanical 
stress [4, 5].
Except for corticosteroids, there is currently no effective treatment for DMD [7]. 
In this chapter, we discuss the potential of mesenchymal stem cells as a therapeutic 
tool for DMD patients. Many researchers prefer the term ‘mesenchymal stromal 
cells’ or ‘mesenchymal progenitors’ to mesenchymal stem cells because mesenchy-
mal stem cells with self-renewal and trilineage differentiation potential are a minor 
subpopulation in tissue-derived primary cultures of mesenchymal cells. In this 
chapter, however, we uniformly refer to them as mesenchymal stem cells.
2. The pathological changes in DMD muscle
The absence of dystrophin causes loss of the dystrophin-associated protein 
complex (DAPC) at the sarcolemma. The sarcolemma lacking the complex becomes 
vulnerable to mechanical stress. In addition, signalling through dystrophin- 
DAPC-associated molecules such as nNOS is disturbed [4, 5]. As a result, myofibres 
die in large numbers by contraction-induced mechanical stress, and to regenerate 
injured myofibres, inflammatory cells begin to remove debris of the muscle tissue; at 
the same time, muscle satellite cells are activated, proliferate and fuse with damaged 
myofibres. In the case of DMD, however, the cycle of degeneration and regeneration 
of myofibres repeats throughout life. Therefore, secondary pathological changes 
gradually develop, including perturbation of calcium homeostasis, activation of 
Ca2+-dependent proteases, mitochondrial dysfunction in myofibres, impaired 
regeneration of myofibres due to exhaustion of satellite cells, prolonged inflamma-
tion, disturbed immune response, fibrosis and fatty infiltration, with poor vascular 
adaptation and functional ischaemia [7]. These secondary pathological changes 
accelerate the disease course of DMD, resulting in severe loss of myofibres and 
Figure 1. 
Deficiency of dystrophin protein at the sarcolemma causes multiple pathological changes in DMD muscle [6, 7].
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muscle atrophy. Therefore, in addition to the restoration of dystrophin protein by 
gene therapy or stem cell therapy, blockage of secondary pathological events is an 
important therapeutic strategy for DMD (Figure 1).
3. Muscle stem cells as a cell-based therapy for DMD
Upon injury, muscle satellite cells are activated, proliferate, and either fuse with 
damaged myofibres or fuse with each other to form new myofibres [8]. In DMD 
muscle, satellite cells compensate for muscle fibre loss in the early stages of the 
disease but eventually are exhausted. As a result, in DMD muscle, the myofibres 
are gradually replaced with fibrous and fatty connective tissue. Therefore, stem cell 
transplantation is expected to be a potential therapy for DMD [9].
There are different kinds of stem cells with myogenic potential in skeletal muscle. 
Muscle satellite cells are authentic unipotent skeletal muscle-specific stem cells [8]. 
Muscle-derived stem cells (MDSCs) [10] and mesangioblasts [11] were reported to 
be multipotent and transplantable via circulation; therefore, they are expected to be 
promising tools for cell-based therapies for DMD. Recently, muscle progenitors were 
induced from pluripotent stem cells as a cell source for cell-based therapy of DMD 
because induced pluripotent stem cells (iPSCs) can be expanded without losing 
pluripotency [12]. Myogenic cells induced from iPSCs are usually at a foetal stage 
and poorly engraft in the muscle of immunodeficient DMD model mice [13, 14].
In addition, muscles affected by muscular dystrophies are in a state of continuous 
inflammation and are characterised by marked and sustained infiltration of inflam-
matory and immune cells with fibrosis and adipose replacement. Such pathological 
microenvironments would not support survival, proliferation, and differentiation of 
the transplanted stem cells. Therefore, researchers have started to consider not only 
the properties of stem cells but also the microenvironment.
4.  Muscle-resident mesenchymal stem cells (progenitors) are 
indispensable for muscle homeostasis
Skeletal muscle regenerates when it is injured. The regeneration process is 
complex but well organised, depending on the interaction among different types 
of cells: muscle stem/progenitor cells, muscle-resident mesenchymal progenitors 
and cells involved in inflammatory and innate and adaptive immune responses. 
Dynamic extracellular matrix (ECM) remodelling is also required for successful 
muscle regeneration. In the case of a minor traumatic injury, muscle regenera-
tion is rapidly completed by the interplay of these cells. In muscular dystrophies, 
however, the degeneration/regeneration process is repeated for a long time, causing 
exhaustion of muscle satellite cells and finally resulting in severe atrophy of skeletal 
muscles with a loss of myofibres and extensive fibrosis and fat deposition [15].
Fibro/adipogenic progenitors (FAPs) are tissue-resident mesenchymal stem 
(or stromal or progenitor) cells [16, 17]. Recently, the necessity of FAPs for 
skeletal muscle regeneration and maintenance was demonstrated using mouse 
models [18]. The authors demonstrated that depletion of FAPs resulted in loss 
of expansion of muscle stem cells (MuSCs) and haematopoietic cells after injury 
and impaired skeletal muscle regeneration [18]. Furthermore, FAP-depleted mice 
under homeostatic conditions exhibited muscle atrophy and a loss of MuSCs, 
revealing that FAPs are essential for long-term homeostatic maintenance of 
skeletal muscle and the MuSC pool [18].
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FAPs have dual functions [19, 20]. In small-scale traumatic muscle injury, they 
are activated, expand and promote muscle regeneration. When regeneration is 
completed, FAPs are cleared from the regenerated muscle. In pathological condi-
tions, such as muscular dystrophies, they continue to proliferate and contribute to 
fibrosis and fatty tissue accumulation.
How is the fate of FAPs regulated? Apparently, FAPs are regulated by signals 
from myogenic cells and immune cells. Altered signals from these cells in dystro-
phic muscle change the pro-regenerative FAPs to fibrotic and adipogenic types. 
Recently, Hogarth et al. reported that annexin A2 accumulation in the myofibre 
matrix promotes adipogenic replacement of FAPs in dysferlin-deficient LGMD2B 
model mice. The authors also showed that an MMP-14 inhibitor, Batimastat, 
inhibited adipogenesis of FAP. The authors speculate that Annexin A2 and MMP-
14 both prolong the inflammatory environment, therefore causing excessive 
expansion of FAP in diseased muscle [21]. Pharmacological inhibition of FAP 
expansion may be a good strategy to prevent fibro/adipogenic changes in dystro-
phic muscles.
The signals that regulate FAPs remain largely unclear. Interestingly, treating  
FAPs of young mdx mice with trichostatin A (TSA), a histone deacetylase 
inhibitor, blocked their fibrotic and adipogenic differentiation and promoted 
a myogenic fate [22] by changing chromatin structure [23]. TSA treatment 
decreased the expression of adipogenic genes and upregulated myogenic genes in 
FAPs [22].
5. Inflammation and immune responses in muscular dystrophies
Inflammatory and immune cells (neutrophils, eosinophils, basophils, macro-
phage NK cells, dendritic cells, T cells, B cells, etc.) are key regulators of muscle 
regeneration. In particular, macrophages orchestrate the regeneration process. In 
the early phase of muscle regeneration, M1 (inflammatory) macrophages remove 
necrotic tissues by phagocytosis and inhibit fusion of myogenic precursor cells. In 
the later stage, M2 (regulatory) macrophages gradually replace M1 macrophages 
and play anti-inflammatory and pro-regenerating roles by promoting the dif-
ferentiation of myogenic cells and the neovascularization of regenerating muscle 
regeneration [24].
DMD muscle, which remains dystrophin-deficient, experiences continuous 
cycles of necrosis and regeneration of myofibres. This causes chronic inflammation 
and evokes T cell-mediated immune responses, which involves the coexistence of 
both M1 and M2 macrophages and T cells in the muscle, and it further damages 
myofibres and exacerbates fibrosis and adipocyte infiltration [6, 25, 26]. Therefore, 
pharmacological inhibition of excess inflammation and immune response is a 
reasonable therapeutic strategy for DMD.
6. Mesenchymal stem cells as a therapeutic tool for DMD
As a therapeutic tool for regenerative medicine, mesenchymal stem cells 
(MSCs) have received significant attention in the recent years due to their high 
growth potential, paracrine effects, immunomodulatory function and few reported 
adverse effects [27, 28]. Since MSCs show relatively low immunogenicity due to low 
expression of major histocompatibility (MHC) antigens and their immunomodu-
lation function, they are being used even in allogeneic settings.
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6.1 Definition
To facilitate research on MSCs, the International Society of Cellular Therapy 
(ISCT) formulated minimal criteria for defining multipotent MSCs in 2006 [29]. 
First, MSCs must be plastic adherent when maintained in standard culture conditions. 
Second, MSCs must express CD105, CD73 and CD90 and must not express CD45, 
CD34, CD14, CD11b, CD79alpha, CD19 and HLA-DR surface molecules. Third, MSCs 
must differentiate into osteoblasts, adipocytes and chondrocytes under standard in 
vitro differentiation protocols [29].
6.2 Preparation
Historically, MSCs were isolated from bone marrow [30–33]. Currently, MSCs 
are shown to exist in the perivascular niche in nearly all tissues and are prepared 
from a variety of tissues, such as the umbilical cord [34], placenta [35], adipose 
tissue [36] and dental tissues [37]. Preparation of MSCs from those tissues is less 
invasive than it is from BM. MSCs from different tissues have similar functions, 
but detailed comparative studies revealed that MSCs of different origins possess 
different properties [38].
6.3 Differentiation
MSCs are multipotent stem cells that undergo self-renewal and differentiate into 
multiple tissues of the mesenchymal lineage and into a non-mesenchymal lineage, 
including neurons, glia, endothelial cells, hepatocytes and β cells in the pancreas 
[27]. This wide range of differentiation capacities is one reason why mesenchymal 
stem cells are being tested in almost 1000 clinical trials in regenerative medicine for 
the musculoskeletal system, nervous system, myocardium, liver, skin and immune 
diseases (http://ClinicalTrial.gov). Importantly, the differentiation potential of 
MSCs varies according to their origin, method of isolation and in vitro propagation 
procedures [39–41].
6.4 Secretome of MSCs
MSCs secrete a variety of bioactive molecules, such as growth factors, che-
mokines and cytokines. These molecules regulate the survival, proliferation and 
differentiation of target cells, promote angiogenesis and tissue repair and modulate 
inflammation and innate or acquired immunity. It is widely accepted that the thera-
peutic effects of MSCs in preclinical and clinical trials are largely due to their para-
crine function [27]. Importantly, the secretome of MSCs varies depending on the age 
of the donor and the niches where the cells reside [42]. Therefore, it is expected that 
the therapeutic effects of MSCs with different origins exert will be different.
6.5 Transplanted MSCs ameliorate dystrophic phenotypes of DMD muscle?
6.5.1 Mechanisms of amelioration of the dystrophic phenotype by MSCs
Recently, there has been considerable interest in the clinical application of MSCs 
for the treatment of muscle diseases. However, the myogenic potential of MSCs is 
controversial.
Sassoli et al. found that myoblast proliferation was greatly enhanced in coculture 
with bone marrow MSCs [43]. Myoblasts after coculture expressed higher levels of 
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Notch-1, a key determinant of myoblast activation and proliferation. Interestingly, 
the effects were mediated by vascular endothelial growth factor (VEGF) secreted by 
MSCs [43]. A VEGFR2 inhibitor, KRN633, inhibited the positive effects of MSC-CM 
on C2C12 cell growth and Notch-1 signalling [43]. Linard et al. showed success-
ful regeneration of rump muscle by local transplantation of bone marrow MSCs 
(BM-MSCs) after severe radiation burn using a pig model [44]. The authors speculate 
that locally injected BM-MSCs secreted growth factors such as VEGF and promoted 
angiogenesis. The authors also showed that MSCs supported the maintenance of the 
satellite cell pool and created a good macrophage M1/M2 balance. Nakamura et al. 
reported that transplantation of MSCs promoted the regeneration of skeletal muscle 
in a rat injury model without differentiation into skeletal myofibres. The report 
suggests that MSCs contribute to the regeneration of skeletal muscle by paracrine 
mechanisms [45]. Maeda et al. reported that BM-MSCs transplanted into peritoneal 
cavities of dystrophin/utrophin double-knockout (dko) mice strongly suppressed 
dystrophic pathology and extended the lifespan of treated mice [46]. The authors 
speculated that CXCL12 and osteopontin from BM-MSCs improved muscle regenera-
tion. Bouglé et al. also reported that human adipose-derived MSCs improved the 
muscle phenotype of DMD mice via the paracrine effects of MSCs [47].
In addition to soluble factors, recent studies demonstrated that MSCs secrete a 
large number of exosomes for intercellular communication [48, 49]. These exosomes 
are now expected to be a therapeutic tool for many diseases [50, 51]. Nakamura et 
al. reported that exosomes from MSCs contained miRNAs that promoted muscle 
regeneration and reduced the fibrotic area [45]. Bier et al. reported that intramuscular 
transplantation of PL-MSCs in mdx mice decreased the serum CK level, reduced 
fibrosis in the diaphragm and cardiac muscles and inhibited inflammation, partly 
via exosomal miR-29c [49]. Thus, MSC exosomes or MSC cytokines may provide a 
cell-free therapeutic strategy as an alternative to transplanting MSCs.
On the other hand, Saito et al. reported that BM-MSCs and periosteum MSCs 
differentiated into myofibres and restored dystrophin expression in mdx mice, 
although the efficiency was low (3%) [52]. Liu et al. showed that FLK-1+ adipose-
derived MSCs restored dystrophin expression in mdx mice [53]. Feng et al. reported 
that intravenously delivered BM-MSCs increased dystrophin expression in mdx 
mice [54]. Vieira et al. reported that intravenously injected human adipose-derived 
MSCs successfully reached the muscle of golden retriever muscular dystrophy 
(GRMD) dogs and that they expressed human dystrophin [55]. Furthermore, 
Park et al. reported that human tonsil-derived MSCs (T-MSCs) differentiated into 
myogenic cells in vitro, and transplantation promoted the recovery of muscle func-
tion, as demonstrated by gait assessment (footprint analysis); furthermore, such 
treatment restored the shape of skeletal muscle in mice with a partial myectomy of 
the gastrocnemius muscle [56]. These reports suggest that MSCs directly contribute 
to the regeneration of myofibres and restore dystrophin expression.
7.  MSCs regulate inflammation and the immune response in muscular 
dystrophies
In response to damage signals, perivascular MSCs are activated and recruit 
inflammatory and immune cells and promote inflammation. At a later stage, MSCs 
begin to suppress inflammation and the immune response. On the other hand, 
MSCs in circulation are reported to selectively home towards damaged tissue 
[57]. Once homed, the inflammatory environment stimulates MSCs to produce a 
large amount of bioactive molecules or to directly interact with inflammatory and 
immune cells to regulate inflammation and the immune response.
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The therapeutic effects of MSCs in preclinical or clinical trials are thought to be 
partly the result of modulation of innate and adaptive immunity [27], especially 
through monocyte/macrophage modulation [28]. Inflammation and immune response 
are part of the pathology of DMD muscle. Therefore, the immunomodulatory func-
tions of MSCs might be useful for the treatment of DMD.
MSCs are supposed to modulate inflammation and the immune response by  
(a) suppressing the maturation and function of dendritic cells [58–60], (b) promoting 
macrophage differentiation towards an M2-like phenotype with high tissue remodel-
ling potential and anti-inflammatory activity [61], (c) inhibiting Th17 generation and 
function [62, 63], (d) inhibiting Th1 cell generation [64], (e) suppressing NK [65, 66] 
and T cytotoxic cell function [66], (f) stimulating the generation of Th2 cells [67] and 
(g) inducing Treg cells [64, 66, 68].
Pinheiro et al. investigated the effects of adipose-derived mesenchymal stem 
cell (AD-MSC) transplantation on dystrophin-deficient mice. Local injection of 
AD-MSCs improved histological phenotypes and muscle function [69]. AD-MSCs 
decreased the muscle content of TNF-α, IL-6, TGF-β1 and oxidative stress but 
increased the levels of VEGF, IL-10 and IL-4 [69]. MSC-derived IL-4 and IL-10 
are reported to convert M1 (pro-inflammatory) macrophages to the M2 (anti-
inflammatory) type and promote satellite cell differentiation [70]. These results 
suggest that transplanted AD-MSCs ameliorated the dystrophic phenotype partly 
by modulating inflammation.
7.1  Suppression of the immune response by MSCs potentiates gene therapy and 
cell-based therapy
In a clinical trial of gene therapy using a dystrophin transgene, T cells specific to 
epitopes of pre-existing dystrophin in revertant fibres were detected, suggesting the 
existence of autoreactive T-cell immunity against dystrophin before treatment [71]. 
Currently, exon skipping therapy to restore the reading frame of the DMD gene, and 
readthrough therapy of premature stop codons (e.g. aminoglycosides or ataluren), 
is being tested in patients with DMD. The treated patients start to produce dystro-
phin, which provides new epitopes to them. Suppression of undesirable immune 
responses against newly produced dystrophin might improve the efficiency of gene 
therapy.
Transplantation of myogenic cells also evokes innate and acquired immune 
responses against transplanted cells in the recipient. Therefore, immunosuppres-
sion by MSCs is expected to improve the engraftment of transplanted cells and 
the therapeutic effects of cell therapy. In addition, MSCs support the survival, 
proliferation, migration and differentiation of myogenic cells by secreting trophic 
factors.
8. Mesenchymal stem cells induced from pluripotent stem cells (iPSCs)
8.1  MSC-like cells induced from human pluripotent stem cells (iMSCs) have 
properties that are different from tissue MSCs
Although BM-MSCs are well studied and widely tested in regenerative medicine, 
the collection procedure for bone marrow is invasive and painful. In addition, adult 
BM-MSCs cannot be expanded in culture beyond 10 passages [72]. To obtain MSCs 
with higher proliferative potential, other sources of MSCs are gaining attention, 
such as the umbilical cord and the placenta. MSCs from these sources proliferate 
better than BM-MSCs but still show limited proliferative activity [38].
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hiPSCs can be expanded in vitro without loss of pluripotency and are therefore 
an ideal source for deriving mesenchymal stem cells of high quality in a large 
quantity [73–75]. In addition, unlike human ES cells, iPSCs are not accompanied 
by ethical concerns. To date, many protocols have been reported for the deviation 
of mesenchymal stem cells from human ES cells/iPS cells [73–77], although the 
difference in properties among iMSCs induced by different protocols remains 
to be determined [73, 74, 77]. For clinical use, iMSCs would be generated from 
well-characterised, pathogen-free, banked iPSCs with known HLA types or from 
patient-specific iPSCs.
8.2  Are MSCs induced from human pluripotent stem cells (iMSCs) ideal for 
clinical use?
MSCs induced from human iPS cells are generally characterised as repro-
grammed, rejuvenated MSCs with high proliferative activity [78]. A previous study 
reported that MSCs from human iPSCs could be expanded for approximately 40 
passages (120 population doublings) without obvious loss of plasticity or onset of 
replicative senescence [79]. In addition, iMSCs have been shown to exhibit potent 
immune-modulatory function and therapeutic properties (Table 1) [80]. Spitzhorn 
et al. reported that iMSCs did not form tumours after transplantation into the liver 
[81], but to exclude residual undifferentiated iPS cells, purification of MSCs by 
FACS using MSC markers and careful evaluation of the risk of tumour formation 
would be required for each preparation.
BM-MSCs Induced MSCs from ES/iPS 
cells
Preparation Autologous or allogeneic, invasive Many protocols for deviation 
scale-up production [73–77]
Proliferation Limited expansion Proliferate faster, greater 
proliferation capacity
Senescence Faster Slower
Quality Inconsistent, heterogeneous depend on 
donor age [82] and health condition, 
and culture condition
Controllable? Closer to foetal 
MSCs less mature than tissue-
derived MSCs
Differentiation Trilineage (adipocytes, osteocytes and 
chondrocytes); hardly differentiate 
into skeletal muscle
Higher osteogenic 
differentiation [74]; poor 
differentiation into adipogenic 
cells [83]
Stemness Lost with expansion Kept for long culture
Safety No tumour formation; pathogens from 
the donors
Genomic instability during the 
expansion of iPSCs; tumorigenic 
potential by residual hiPSCs
Paracrine effects Inhibit apoptosis, promote proliferation and differentiation of the cells, 
promote tissue regeneration; different secretome [87]
Immunomodulation 
function
Regulate inflammation, innate and 
acquired immunity
Stronger than BM-MSCs?  
[74, 80]
Suitable for cell therapy? Being tested in preclinical and clinical 
trials without serious side effects
Unlimited source of MSCs; 
autologous MSCs are available
Genome editing Difficult Possible
Table 1. 
Comparison of properties of human iMSCs with human BM-MSCs.
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8.3 iMSCs for muscle disease
The therapeutic potential of iMSCs has been tested in bone regeneration [80, 84],  
intestinal healing [85], myocardial disorders [86, 87], limb ischaemia [79] and 
autoimmune disease [88, 89]. In these studies, iMSCs showed therapeutic effects 
that were comparable or superior to those of tissue MSCs. In the muscular dys-
trophy field, there are only a small number of reports so far. Jeong et al. reported 
that iMSCs transplanted into the tibialis anterior of mdx mice decreased oxidative 
damage, as evidenced by a reduction in nitrotyrosine levels, and achieved normal 
dystrophin expression levels [90]. Since direct differentiation of MSCs into myo-
genic cells is generally limited, the observed effects of iMSCs might be due to the 
secretion of bioactive molecules that exert immunomodulatory effects and provide 
trophic support to myogenic cells.
Importantly, however, Liu et al. recently reported that transplantation of 
BM-MSCs from C57BL/6 mice aggravated inflammation, oxidative stress and fibro-
sis and impaired regeneration of contusion-injured C57/Bl6 muscle [91]. Although 
the mechanisms are not clear, the microenvironment in contusion-damaged muscle 
might induce the transformation of MSCs into the fibrotic phenotype. Caution 
might be warranted in the clinical application of MSCs to highly fibrotic muscle.
9. Conclusions
MSCs are multifunctional cells. MSCs secrete trophic factors that help regenerate 
myofibres. In addition, MSCs suppress inflammation and the immune response in 
dystrophic mice to protect muscle. MSCs are also expected to support the engraftment 
of transplanted myogenic cells in recipient muscle. Fortunately, recent technology 
gives us an option to derive MSC-like cells from pluripotent stem cells. Thus, MSCs are 
a promising next-generation tool for cell-based therapy of DMD (Figure 2).
Figure 2. 
Mesenchymal stem cells ameliorate the dystrophic phenotype of DMD muscle. Mesenchymal stem-like cells 
can be derived from human iPSCs (iMSCs). MSCs, which arrive in the muscle either through direction 
transplantation or via circulation, secrete a variety of bioactive molecules that promote angiogenesis and 
support the proliferation and differentiation of satellite cells, thereby promoting muscle regeneration. MSCs 
also suppress excess inflammatory and immune responses. Whether transplanted MSCs can directly modulate 
the phenotype of FAPs (resident MSCs) to inhibit fibrosis and fatty replacement remains to be determined. 
Abbreviations: DC, dendritic cells; NK, natural killer cells; Neu, neutrophil; Mø, macrophage; T, T 
lymphocytes; B, B lymphocyte.
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